LivaNova PLC (NASDAQ:LIVN) Receives $69.17 Average Price Target from Analysts

Shares of LivaNova PLC (NASDAQ:LIVNGet Free Report) have received a consensus rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $69.17.

Several brokerages have issued reports on LIVN. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 target price on the stock. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Finally, Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th.

View Our Latest Stock Analysis on LivaNova

Institutional Investors Weigh In On LivaNova

Hedge funds have recently made changes to their positions in the stock. Fifth Third Bancorp lifted its stake in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the period. Hexagon Capital Partners LLC lifted its stake in shares of LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares during the period. Lazard Asset Management LLC bought a new stake in shares of LivaNova in the first quarter valued at about $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova in the second quarter valued at about $88,000. Finally, Central Pacific Bank Trust Division bought a new stake in shares of LivaNova in the third quarter valued at about $178,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $50.50 on Tuesday. LivaNova has a one year low of $43.15 and a one year high of $64.47. The stock has a fifty day moving average of $52.25 and a 200-day moving average of $51.94. The company has a market capitalization of $2.74 billion, a PE ratio of 120.24 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

About LivaNova

(Get Free Report

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Articles

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.